PMX-53 | CAS#219639-75-5 | C5aR(CD88) antagonist

MedKoo Cat#: 530417 | Name: PMX-53

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PMX-53 is a dual C5aR(CD88) antagonist and Mas-related gene 2 (MrgX2) agonist. PMX-53 inhibits C5a-induced hypernociception in rats, inhibits lung metastasis in a mouse breast cancer model and reduces atherosclerotic lesions in a mouse model of atherosclerosis.

Chemical Structure

PMX-53

CAS#219639-75-5

Theoretical Analysis

MedKoo Cat#: 530417

Name: PMX-53

CAS#: 219639-75-5

Chemical Formula: C47H65N11O7

Exact Mass: 895.5068

Molecular Weight: 896.11

Elemental Analysis: C, 63.00; H, 7.31; N, 17.19; O, 12.50

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

PMX 53; PMX 53; PMX53; Ac-Phe-cyclo(Orn-Pro-D-Cha-Trp-Arg); AcPhe(ornithine-Pro-cyclohexylamine-Trp-Arg. AcPhe(ornithine-Pro-cyclohexylamine-Trp-Arg)

IUPAC/Chemical Name

(S)-N-((3R,6S,9S,15S,20aS)-6-((1H-indol-3-yl)methyl)-3-(cyclohexylmethyl)-9-(3-guanidinopropyl)-1,4,7,10,16-pentaoxoicosahydropyrrolo[1,2-a][1,4,7,10,13]pentaazacyclooctadecin-15-yl)-2-acetamido-3-phenylpropanamide

InChi Key

YOKBGCTZYPOSQM-HPSWDUTRSA-N

InChi Code

InChI=1S/C47H65N11O7/c1-29(59)53-37(25-30-13-4-2-5-14-30)42(61)55-36-20-11-22-50-41(60)35(19-10-23-51-47(48)49)54-44(63)39(27-32-28-52-34-18-9-8-17-33(32)34)56-43(62)38(26-31-15-6-3-7-16-31)57-45(64)40-21-12-24-58(40)46(36)65/h2,4-5,8-9,13-14,17-18,28,31,35-40,52H,3,6-7,10-12,15-16,19-27H2,1H3,(H,50,60)(H,53,59)(H,54,63)(H,55,61)(H,56,62)(H,57,64)(H4,48,49,51)/t35-,36-,37-,38+,39-,40-/m0/s1

SMILES Code

N=C(NCCC[C@H](NC([C@@H](NC([C@H](NC([C@H]1N(CCC1)C([C@@H](NC([C@@H](NC(C)=O)CC2=CC=CC=C2)=O)CCCN3)=O)=O)CC4CCCCC4)=O)CC5=CNC6=C5C=CC=C6)=O)C3=O)N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 896.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hajishengallis G, Maekawa T, Abe T, Hajishengallis E, Lambris JD. Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches. Adv Exp Med Biol. 2015;865:57-74. doi: 10.1007/978-3-319-18603-0_4. Review. PubMed PMID: 26306443; PubMed Central PMCID: PMC4562417. 2: Wu H, Zeng M, Cho EY, Jiang W, Sha O. The Origin, Expression, Function and Future Research Focus of a G Protein-coupled Receptor, Mas-related Gene X2 (MrgX2). Prog Histochem Cytochem. 2015 Jul;50(1-2):11-7. doi: 10.1016/j.proghi.2015.06.001. Review. PubMed PMID: 26106044. 3: Benson MJ, Thomas NK, Talwar S, Hodson MP, Lynch JW, Woodruff TM, Borges K. A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models. Neurobiol Dis. 2015 Apr;76:87-97. doi: 10.1016/j.nbd.2015.02.004. PubMed PMID: 25681535. 4: Halai R, Bellows-Peterson ML, Branchett W, Smadbeck J, Kieslich CA, Croker DE, Cooper MA, Morikis D, Woodruff TM, Floudas CA, Monk PN. Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. Eur J Pharmacol. 2014 Dec 15;745:176-81. doi: 10.1016/j.ejphar.2014.10.041. PubMed PMID: 25446428; PubMed Central PMCID: PMC4263610. 5: Dong H, Shan F, Sun Q, Yang BX, Li CP. The cyclic hexapeptide AcF attenuates sepsis-induced acute lung injury and mortality in rats. Eur Rev Med Pharmacol Sci. 2014;18(18):2727-35. PubMed PMID: 25317810. 6: Li L, Xiong ZY, Qian ZM, Zhao TZ, Feng H, Hu S, Hu R, Ke Y, Lin J. Complement C5a is detrimental to histological and functional locomotor recovery after spinal cord injury in mice. Neurobiol Dis. 2014 Jun;66:74-82. doi: 10.1016/j.nbd.2014.02.008. PubMed PMID: 24607885. 7: Zhang C, Li Y, Wang C, Wu Y, Du J. Antagonist of C5aR prevents cardiac remodeling in angiotensin II-induced hypertension. Am J Hypertens. 2014 Jun;27(6):857-64. doi: 10.1093/ajh/hpt274. PubMed PMID: 24419904. 8: Li G, Fan RM, Chen JL, Wang CM, Zeng YC, Han C, Jiao S, Xia XP, Chen W, Yao ST. Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage. Clin Exp Immunol. 2014 Feb;175(2):285-95. doi: 10.1111/cei.12220. PubMed PMID: 24117111; PubMed Central PMCID: PMC3892419. 9: Croker DE, Halai R, Fairlie DP, Cooper MA. C5a, but not C5a-des Arg, induces upregulation of heteromer formation between complement C5a receptors C5aR and C5L2. Immunol Cell Biol. 2013 Nov-Dec;91(10):625-33. doi: 10.1038/icb.2013.48. PubMed PMID: 24060963. 10: Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, DeAngelis RA, Lambris JD, Coukos G, Scholler N. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia. 2012 Nov;14(11):994-1004. PubMed PMID: 23226093; PubMed Central PMCID: PMC3514739. 11: Reis ES, Chen H, Sfyroera G, Monk PN, Köhl J, Ricklin D, Lambris JD. C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay. J Immunol. 2012 Nov 15;189(10):4797-805. doi: 10.4049/jimmunol.1200834. PubMed PMID: 23041570; PubMed Central PMCID: PMC3521166. 12: Kidd LJ, Cowling NR, Wu AC, Kelly WL, Forwood MR. Selective and non-selective cyclooxygenase inhibitors delay stress fracture healing in the rat ulna. J Orthop Res. 2013 Feb;31(2):235-42. doi: 10.1002/jor.22203. PubMed PMID: 22847634. 13: Sahbaie P, Li X, Shi X, Clark JD. Roles of Gr-1+ leukocytes in postincisional nociceptive sensitization and inflammation. Anesthesiology. 2012 Sep;117(3):602-12. doi: 10.1097/ALN.0b013e3182655f9f. PubMed PMID: 22820848; PubMed Central PMCID: PMC3427475. 14: Lappas M, Woodruff TM, Taylor SM, Permezel M. Complement C5A regulates prolabor mediators in human placenta. Biol Reprod. 2012 Jun 28;86(6):190. doi: 10.1095/biolreprod.111.098475. PubMed PMID: 22441801. 15: Recknagel S, Bindl R, Kurz J, Wehner T, Schoengraf P, Ehrnthaller C, Qu H, Gebhard F, Huber-Lang M, Lambris JD, Claes L, Ignatius A. C5aR-antagonist significantly reduces the deleterious effect of a blunt chest trauma on fracture healing. J Orthop Res. 2012 Apr;30(4):581-6. doi: 10.1002/jor.21561. PubMed PMID: 21922535; PubMed Central PMCID: PMC3244519. 16: Iyer A, Woodruff TM, Wu MC, Stylianou C, Reid RC, Fairlie DP, Taylor SM, Brown L. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol. 2011 Nov;58(5):479-86. doi: 10.1097/FJC.0b013e31822a7a09. PubMed PMID: 21753735. 17: Jang JH, Liang D, Kido K, Sun Y, Clark DJ, Brennan TJ. Increased local concentration of complement C5a contributes to incisional pain in mice. J Neuroinflammation. 2011 Jul 7;8:80. doi: 10.1186/1742-2094-8-80. PubMed PMID: 21736743; PubMed Central PMCID: PMC3141504. 18: Suetsugu-Maki R, Maki N, Fox TP, Nakamura K, Cowper Solari R, Tomlinson CR, Qu H, Lambris JD, Tsonis PA. A complement receptor C5a antagonist regulates epithelial to mesenchymal transition and crystallin expression after lens cataract surgery in mice. Mol Vis. 2011 Apr 19;17:949-64. PubMed PMID: 21541266; PubMed Central PMCID: PMC3084220. 19: Manthey HD, Thomas AC, Shiels IA, Zernecke A, Woodruff TM, Rolfe B, Taylor SM. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J. 2011 Jul;25(7):2447-55. doi: 10.1096/fj.10-174284. PubMed PMID: 21490292. 20: Subramanian H, Kashem SW, Collington SJ, Qu H, Lambris JD, Ali H. PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells. Mol Pharmacol. 2011 Jun;79(6):1005-13. doi: 10.1124/mol.111.071472. PubMed PMID: 21441599; PubMed Central PMCID: PMC3102546.